Key terms
About PYXS
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PYXS news
Mar 28
6:40am ET
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Spectral AI (MDAI) and Pyxis Oncology (PYXS)
Mar 27
5:12pm ET
Pyxis Oncology files to sell 10.46M shares of common stock for holders
Mar 27
7:35am ET
Pyxis Oncology obtains $8M payment for the sale of royalty rights
Mar 24
9:26pm ET
Optimistic Buy Rating for Pyxis Oncology’s PYX-201 Based on Strong Safety Profile and Promising Therapeutic Potential
Mar 22
6:38am ET
Pyxis Oncology (PYXS) Gets a Buy from RBC Capital
Mar 22
6:28am ET
Buy Rating Affirmed for Pyxis Oncology on Strong Clinical and Financial Prospects
Mar 22
6:16am ET
Buy Rating on Pyxis Oncology: Promising PYX-201’s Safety Profile and Strategic Focus on Solid Tumors
Mar 22
6:14am ET
Pyxis Oncology price target raised to $7 from $4 at H.C. Wainwright
Mar 21
5:45pm ET
Buy Rating Affirmed: Pyxis Oncology’s Financial Health and Promising Drug Candidate PYX-201 Bolster Optimism
Mar 21
8:02am ET
Pyxis Oncology Releases Updated Corporate Presentation
Mar 21
7:36am ET
Pyxis Oncology expects resources to fund operations into 2H26
Mar 21
7:35am ET
Pyxis Oncology reports 2023 EPS ($1.85), consensus ($1.95)
Mar 19
1:38am ET
Pyxis Oncology (PYXS) Receives a Buy from Leerink Partners
Mar 13
4:43pm ET
Pyxis Oncology Bolsters Board with New Independent Director
Mar 13
8:27am ET
Pyxis Oncology appoints Santhosh Palani to board of directors
Feb 28
7:12am ET
Pyxis Oncology Secures $50M Through Private Placement Deal
Feb 27
8:17am ET
Pyxis Oncology to sell 8.85M shares at $4.78 in private placement
Feb 09
6:15am ET
Buy Rating for Pyxis Oncology: Advancing ADC Innovation and Immuno-Oncology Pipeline
Feb 09
6:08am ET
Pyxis Oncology initiated with a Buy at BTIG
Jan 23
6:14am ET
Pyxis Oncology initiated with an Outperform at Leerink
No recent press releases are available for PYXS
PYXS Financials
Key terms
Ad Feedback
PYXS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PYXS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
